Table 1 Characteristics of patients

Age (mean ± SD, years)

56.8 ± 11.9

55.4 ± 11.8

0.302

60.6 ± 14.0

64.0 ± 12.3

0.182

Gender [male/female, n (%)]

97 (72.4)/37 (27.6)

165 (84.2)/31 (15.8)

0.009

37 (78.7)/10 (21.3)

47 (78.3)/13 (21.7)

0.961

Metastatic site [n (%)]

 Lymph node

78 (58.2)

–

–

18 (38.3)

–

–

 Lung

14 (10.5)

–

–

7 (14.9)

–

–

 Gastrointestinal tract

7 (5.2)

–

–

1 (2.1)

–

–

 Adrenal gland

5 (3.7)

–

–

5 (10.6)

–

–

 Bone

4 (3.0)

–

–

3 (6.4)

–

–

 Pleuroperitonea

2 (1.5)

–

–

2 (4.3)

–

–

 Multiple sites

24 (17.9)

–

–

11 (23.4)

–

–

Size (mean ± SD, cm)

7.6 ± 3.9

5.5 ± 3.6

< 0.001

7.7 ± 3.6

5.9 ± 4.0

0.018

PVTT [n (%)]

86 (64.2)

60 (30.6)

< 0.001

16 (34.0)

8 (13.3)

0.011

Infection

35 (26.1)

10 (5.1)

< 0.001

23 (48.9)

14 (23.3)

0.006

CA125 (U/mL)

 Levels (mean ± SD)

138.1 ± 249.9

85.5 ± 218.9

0.049

292.3 ± 349.5

170.3 ± 268.7

0.051

 Positive rates [> 13.9*, n (%)]

111 (82.9)

100 (51.0)

< 0.001

24 (51.1)

43 (71.7)

0.029

AFP (ng/mL)

 Levels (mean ± SD)

476.6 ± 680.1

384.9 ± 513.3

0.187

511.4 ± 735.9

422.6 ± 651.2

0.510

 Positive rates [n (%)]

  ≥ 20

70 (52.2)

108 (55.1)

0.608

32 (68.1)

35 (58.3)

0.301

  ≥ 200

57 (42.5)

71 (36.2)

0.248

26 (55.3)

35 (58.3)

0.755

  ≥ 400

84 (62.7)

132 (67.3)

0.382

32 (68.1)

40 (66.7)

0.877